Rhumbline Advisers Buys Shares of 32,547 Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

Rhumbline Advisers purchased a new position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) in the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 32,547 shares of the company’s stock, valued at approximately $79,000. Rhumbline Advisers owned 0.07% of Werewolf Therapeutics at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the stock. Lighthouse Investment Partners LLC acquired a new position in shares of Werewolf Therapeutics in the 4th quarter valued at about $87,000. Denali Advisors LLC acquired a new stake in Werewolf Therapeutics in the 1st quarter valued at approximately $172,000. Bank of New York Mellon Corp bought a new position in Werewolf Therapeutics in the 2nd quarter worth approximately $165,000. Acadian Asset Management LLC lifted its holdings in shares of Werewolf Therapeutics by 119.8% during the first quarter. Acadian Asset Management LLC now owns 172,883 shares of the company’s stock worth $1,119,000 after buying an additional 94,212 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Werewolf Therapeutics by 26.8% in the first quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company’s stock valued at $7,176,000 after acquiring an additional 233,909 shares during the period. 64.84% of the stock is owned by institutional investors and hedge funds.

Werewolf Therapeutics Stock Performance

Werewolf Therapeutics stock opened at $2.12 on Tuesday. The firm has a market capitalization of $92.12 million, a P/E ratio of -1.94 and a beta of 0.46. The stock has a fifty day moving average price of $2.20 and a two-hundred day moving average price of $3.72. Werewolf Therapeutics, Inc. has a 52-week low of $1.57 and a 52-week high of $8.19. The company has a debt-to-equity ratio of 0.24, a current ratio of 12.13 and a quick ratio of 12.13.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The business had revenue of $1.14 million during the quarter, compared to analyst estimates of $2.00 million. Werewolf Therapeutics had a negative return on equity of 48.25% and a negative net margin of 578.80%. As a group, analysts anticipate that Werewolf Therapeutics, Inc. will post -1.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on HOWL shares. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Werewolf Therapeutics in a research report on Tuesday, July 2nd. Wedbush restated an “outperform” rating and set a $9.00 price objective on shares of Werewolf Therapeutics in a research report on Monday, June 3rd. Finally, JMP Securities reissued a “market outperform” rating and issued a $12.00 price target on shares of Werewolf Therapeutics in a report on Wednesday, June 26th.

Werewolf Therapeutics Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.